Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.0424552429667518 -0.0542199488491048 -0.0534526854219948 -0.0585677749360614
Stock impact report

Dr. Reddy’s Q1 FY20 Financial Results

Dr. Reddy's Laboratories Ltd (RDY) 
US:NYSE Investor Relations: drreddys.com/investors
Company Research Source: Business Wire
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended June 30, 2019 under International Financial Reporting Standards (IFRS).RevenuesRs.3,844 Cr [YoY: 3% Up, QoQ: 4% Dc]    Gross Margin 51.7% [Q1 FY19: 55.7%; Q4 FY19: 52.4%]     SG&A expensesRs.1,207 Cr [YoY: Flat; QoQ: 3% Dc]    R&D expenses Rs.361 Cr [9.4% of Revenues]    Profit before TaxRs.850 Cr  Show less Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
RDY alerts

from News Quantified
Opt-in for
RDY alerts

from News Quantified